This article first appeared on GuruFocus .
-
Revenue:Increased to RMB18.6 million from nil, primarily due to an upfront payment from a licensing and technology transfer agreement with Joincare Group.
-
Other Income:RMB68.8 million, a decrease of 51.3% from RMB141.4 million in 2024, mainly due to lower bank interest income and changes in government grant income.
-
Cash and Cash Equivalents:RMB1,941 billion as of December 31, 2025, expected to support operations beyond 2028.
-
Research and Development Expenses:Declined by 14.8% to RMB212.9 million from RMB249.8 million in 2024, reflecting increased third-party contract and employee costs.
-
Administrative Expenses:RMB109.5 million, a decrease of 28.5% from RMB153.2 million in 2024, due to lower employee costs and adjustments in senior management compensation.
-
Warning! GuruFocus has detected 2 Warning Signs with STU:7SS.
-
Is STU:7SS fairly valued? Test your thesis with our free DCF calculator.
Release Date: March 20, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Brii Biosciences Ltd ( STU:7SS ) made significant progress in advancing their HBV clinical programs, with key data reported and studies moving towards a registrational development pathway.
-
The company successfully completed enrollment for their Phase IIb ENRICH and ENHANCE studies, with readouts expected in the second half of the year.
-
Brii Biosciences Ltd ( STU:7SS ) expanded their discovery capabilities by integrating AI-enabled discovery tools and building new research infrastructure, positioning them to accelerate future therapy discoveries.
-
The company maintained a strong cash position, with bank deposits and cash equivalents supporting operations beyond 2028.
-
Brii Biosciences Ltd ( STU:7SS ) effectively controlled operational costs, with a 14.8% reduction in research and development expenses and a 28.5% decline in administrative expenses for 2025.
Negative Points
-
Revenue for Brii Biosciences Ltd ( STU:7SS ) was primarily driven by a one-time upfront payment, indicating a lack of recurring revenue streams.
-
Other income decreased by 51.3% compared to the previous year, mainly due to lower bank interest income and changes in income from government grants.
-
The company faces uncertainties in achieving a functional cure for HBV, as ongoing studies are still in the Phase IIb stage.
-
Brii Biosciences Ltd ( STU:7SS ) has not yet disclosed specific areas of focus for their expanded discovery capabilities, leaving investors uncertain about future directions.
-
The company is still exploring partnership opportunities for non-core assets, indicating potential challenges in advancing these programs independently.
Q & A Highlights
Q: Could you help frame your expectations for the data from the ENRICH and ENHANCE studies, and what do you hope to see to potentially go forward into Phase III? A: We expect data to emerge this year, providing insights into our path forward. For ENRICH, we're looking to identify patients with a good immune response from BRII-179, translating to higher response rates. For ENHANCE, we're comparing the triple combination of BRII-179, elebsiran, and PEG interferon against the double combination to see if it yields better results. We're aiming for a 10% or better response improvement over the ENSURE study.
Q: What type of candidates or therapy areas might you focus on with your expanded discovery capabilities? A: We are expanding beyond infectious diseases to include more chronic and common diseases with unmet medical needs. Specific areas have not been disclosed yet, but we plan to share more information later this year.
Q: Any updates on your partnering strategy for non-core assets? A: We continue to explore partnerships for our HIV program and ex-China rights for soralimixin. We are in discussions with several parties and will share more definitive progress when available.
Q: What's the development strategy for Brii's discovery programs? Will the company carry on the program to late-stage development by itself or seek partnerships? A: We are leveraging China's efficient ecosystem for early discovery and clinical development. We have built labs in Beijing and Shanghai and expect to move programs towards clinical development this year. We aim to realize value through partnerships but are open to continuing development independently, depending on expertise and market potential.
Q: How does Brii plan to maintain alignment with shareholder interests? A: In 2025, the Board approved a reduction in senior management's annual bonuses for 2025 and 2026, aligning management incentives with long-term shareholder value. Executive bonuses will be reduced to approximately one-fourth of their original level, ensuring compensation aligns with business performance and capital market outcomes.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
